125 related articles for article (PubMed ID: 15215131)
21. Hot-spot consensus of fluoroquinolone-mediated DNA cleavage by Gram-negative and Gram-positive type II DNA topoisomerases.
Richter SN; Giaretta G; Comuzzi V; Leo E; Mitchenall LA; Fisher LM; Maxwell A; Palumbo M
Nucleic Acids Res; 2007; 35(18):6075-85. PubMed ID: 17766248
[TBL] [Abstract][Full Text] [Related]
22. Fragment-based discovery of DNA gyrase inhibitors targeting the ATPase subunit of GyrB.
Mesleh MF; Cross JB; Zhang J; Kahmann J; Andersen OA; Barker J; Cheng RK; Felicetti B; Wood M; Hadfield AT; Scheich C; Moy TI; Yang Q; Shotwell J; Nguyen K; Lippa B; Dolle R; Ryan MD
Bioorg Med Chem Lett; 2016 Feb; 26(4):1314-8. PubMed ID: 26786695
[TBL] [Abstract][Full Text] [Related]
23. Characterization of the DNA gyrase from the thermoacidophilic archaeon Thermoplasma acidophilum.
Yamashiro K; Yamagishi A
J Bacteriol; 2005 Dec; 187(24):8531-6. PubMed ID: 16321962
[TBL] [Abstract][Full Text] [Related]
24. Antimicrobial susceptibility and molecular characterization of avian pathogenic Escherichia coli isolates.
Zhao S; Maurer JJ; Hubert S; De Villena JF; McDermott PF; Meng J; Ayers S; English L; White DG
Vet Microbiol; 2005 May; 107(3-4):215-24. PubMed ID: 15863280
[TBL] [Abstract][Full Text] [Related]
25. Overexpression and purification of bacterial DNA gyrase.
Maxwell A; Howells AJ
Methods Mol Biol; 1999; 94():135-44. PubMed ID: 12844869
[No Abstract] [Full Text] [Related]
26. Discovery of a novel azaindole class of antibacterial agents targeting the ATPase domains of DNA gyrase and Topoisomerase IV.
Manchester JI; Dussault DD; Rose JA; Boriack-Sjodin PA; Uria-Nickelsen M; Ioannidis G; Bist S; Fleming P; Hull KG
Bioorg Med Chem Lett; 2012 Aug; 22(15):5150-6. PubMed ID: 22814212
[TBL] [Abstract][Full Text] [Related]
27. Contribution of mutations in DNA gyrase and topoisomerase IV genes to ciprofloxacin resistance in Escherichia coli clinical isolates.
Bansal S; Tandon V
Int J Antimicrob Agents; 2011 Mar; 37(3):253-5. PubMed ID: 21236644
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms of action and resistance of older and newer fluoroquinolones.
Hooper DC
Clin Infect Dis; 2000 Aug; 31 Suppl 2():S24-8. PubMed ID: 10984324
[TBL] [Abstract][Full Text] [Related]
29. Amycolamicin: a novel broad-spectrum antibiotic inhibiting bacterial topoisomerase.
Sawa R; Takahashi Y; Hashizume H; Sasaki K; Ishizaki Y; Umekita M; Hatano M; Abe H; Watanabe T; Kinoshita N; Homma Y; Hayashi C; Inoue K; Ohba S; Masuda T; Arakawa M; Kobayashi Y; Hamada M; Igarashi M; Adachi H; Nishimura Y; Akamatsu Y
Chemistry; 2012 Dec; 18(49):15772-81. PubMed ID: 23129443
[TBL] [Abstract][Full Text] [Related]
30. New inhibitors of bacterial topoisomerase GyrA/ParC subunits.
Black MT; Coleman K
Curr Opin Investig Drugs; 2009 Aug; 10(8):804-10. PubMed ID: 19649925
[TBL] [Abstract][Full Text] [Related]
31. Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activities.
Singh SB; Goetz MA; Smith SK; Zink DL; Polishook J; Onishi R; Salowe S; Wiltsie J; Allocco J; Sigmund J; Dorso K; de la Cruz M; Martín J; Vicente F; Genilloud O; Donald RG; Phillips JW
Bioorg Med Chem Lett; 2012 Dec; 22(23):7127-30. PubMed ID: 23084277
[TBL] [Abstract][Full Text] [Related]
32. Design and synthesis of peptides from bacterial ParE toxin as inhibitors of topoisomerases.
Barbosa LC; Garrido SS; Garcia A; Delfino DB; Santos Ldo N; Marchetto R
Eur J Med Chem; 2012 Aug; 54():591-6. PubMed ID: 22749642
[TBL] [Abstract][Full Text] [Related]
33. Staphylococcus simulans Recombinant Lysostaphin: Production, Purification, and Determination of Antistaphylococcal Activity.
Boksha IS; Lavrova NV; Grishin AV; Demidenko AV; Lyashchuk AM; Galushkina ZM; Ovchinnikov RS; Umyarov AM; Avetisian LR; Chernukha MIu; Shaginian IA; Lunin VG; Karyagina AS
Biochemistry (Mosc); 2016 May; 81(5):502-10. PubMed ID: 27297900
[TBL] [Abstract][Full Text] [Related]
34. Topoisomerase IV, alone, unknots DNA in E. coli.
Deibler RW; Rahmati S; Zechiedrich EL
Genes Dev; 2001 Mar; 15(6):748-61. PubMed ID: 11274059
[TBL] [Abstract][Full Text] [Related]
35. Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.
Pan XS; Yague G; Fisher LM
Antimicrob Agents Chemother; 2001 Nov; 45(11):3140-7. PubMed ID: 11600369
[TBL] [Abstract][Full Text] [Related]
36. Escherichia coli topoisomerase IV. Purification, characterization, subunit structure, and subunit interactions.
Peng H; Marians KJ
J Biol Chem; 1993 Nov; 268(32):24481-90. PubMed ID: 8227000
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis and biological evaluation of α-substituted isonipecotic acid benzothiazole analogues as potent bacterial type II topoisomerase inhibitors.
Axford LC; Agarwal PK; Anderson KH; Andrau LN; Atherall J; Barker S; Bennett JM; Blair M; Collins I; Czaplewski LG; Davies DT; Gannon CT; Kumar D; Lancett P; Logan A; Lunniss CJ; Mitchell DR; Offermann DA; Palmer JT; Palmer N; Pitt GR; Pommier S; Price D; Narasinga Rao B; Saxena R; Shukla T; Singh AK; Singh M; Srivastava A; Steele C; Stokes NR; Thomaides-Brears HB; Tyndall EM; Watson D; Haydon DJ
Bioorg Med Chem Lett; 2013 Dec; 23(24):6598-603. PubMed ID: 24239017
[TBL] [Abstract][Full Text] [Related]
38. Testing potential gyrase inhibitors of bacterial DNA gyrase: a comparison of the supercoiling inhibition assay and "cleavable complex" assay.
Barrett JF; Bernstein JI; Krause HM; Hilliard JJ; Ohemeng KA
Anal Biochem; 1993 Oct; 214(1):313-7. PubMed ID: 8250240
[TBL] [Abstract][Full Text] [Related]
39. Streptococcus pneumononiae gyrase ATPase: development and validation of an assay for inhibitor discovery and characterization.
Miller JR; Herberg JT; Tomilo M; McCroskey MC; Feilmeier BJ
Anal Biochem; 2007 Jun; 365(1):132-43. PubMed ID: 17395144
[TBL] [Abstract][Full Text] [Related]
40. Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships.
Charifson PS; Grillot AL; Grossman TH; Parsons JD; Badia M; Bellon S; Deininger DD; Drumm JE; Gross CH; LeTiran A; Liao Y; Mani N; Nicolau DP; Perola E; Ronkin S; Shannon D; Swenson LL; Tang Q; Tessier PR; Tian SK; Trudeau M; Wang T; Wei Y; Zhang H; Stamos D
J Med Chem; 2008 Sep; 51(17):5243-63. PubMed ID: 18690678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
